Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Flow cytometric chromosome classification
Flow cytometric chromosome classification has been routinely used in the analysis of mammalian...
9 steps to validate your life science storage
Good manufacturing practice regulators in Australia have sharpened their focus on life...
[eBook] The 21st century lab: your roadmap for transformation
Reinventing laboratory informatics to accelerate...
